奇正藏药(002287) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of CNY 2,337,864,102.43, representing a year-on-year increase of 14.31%[6] - Operating profit for the period was CNY 649,626,550.89, a slight increase of 0.50% compared to the previous year[6] - The net profit attributable to shareholders of the listed company was CNY 575,483,673.63, showing a decrease of 0.98% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 423,390,400.09, an increase of 14.44% from the previous year[5] - Basic earnings per share were CNY 1.0855, down 1.07% from CNY 1.0972 in the previous year[5] Asset and Equity Position - Total assets at the end of the reporting period were CNY 6,776,776,430.85, an increase of 7.59% from the beginning of the period[5] - Shareholders' equity attributable to the listed company was CNY 4,057,787,506.30, up 9.07% from the beginning of the period[5] - The company's share capital increased slightly by 0.17% to CNY 531,085,718.00[5] - The net asset per share attributable to shareholders increased to CNY 7.39, a rise of 9.32% from CNY 6.76[5] Return on Investment - The weighted average return on net assets decreased to 14.91%, down 2.24 percentage points from 17.15%[5]